George Beaver, MD
Family Medicine · Columbia, SCNPI 1073533832
Payments from drug & device makers
Across 158 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$565
- Pfizer$232
- Lilly USA, LLC$213
- Amgen$197
- Novo Nordisk$192
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$177
- plus $975 from 25 others
What the payments were for
- Food & beverage$2,551100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 34 | $565 |
| Pfizer | 15 | $232 |
| Lilly USA, LLC | 14 | $213 |
| Amgen | 13 | $197 |
| Novo Nordisk | 11 | $192 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $177 |
| Exact Sciences | 7 | $118 |
| AbbVie | 6 | $113 |
| Johnson & Johnson | 6 | $80 |
| GSK | 5 | $75 |
| Amarin Pharma, Inc. | 5 | $69 |
| Astellas Pharma US Inc | 3 | $54 |
| Ironshore Pharmaceuticals Inc. | 3 | $53 |
| Novartis | 3 | $53 |
| Abbott | 2 | $41 |
| Bayer | 2 | $37 |
| Merck | 2 | $35 |
| Sanofi Pasteur Inc. | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Cvrx, Inc. | 1 | $20 |
| Shield Therapeutics Inc | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Aytu Biopharma, Inc. | 1 | $14 |
| Corcept Therapeutics | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Bausch Health US, LLC | 1 | $12 |
| Boston Scientific | 1 | $11 |
How this compares
$2,551 in reported general payments places this provider in the 75th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 85 | $89,619 |
| JardianceEmpagliflozin | 72 | $81,977 |
| OzempicSemaglutide | 61 | $81,443 |
| FarxigaDapagliflozin Propanediol | 70 | $56,910 |
| TrulicityDulaglutide | 34 | $41,643 |
| MyrbetriqMirabegron | 32 | $36,210 |
| RybelsusSemaglutide | 19 | $27,871 |
| EliquisApixaban | 36 | $27,514 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $17,788 |
| XareltoRivaroxaban | 14 | $17,105 |
| JanuviaSitagliptin Phosphate | 19 | $13,314 |
| Rosuvastatin Calcium | 390 | $9,295 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $8,054 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,644 |
| Atorvastatin Calcium | 578 | $7,592 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $213 | $131,262119 claims |
| Novo NordiskOzempic, Rybelsus | $192 | $109,31480 claims |
| AstraZenecaFarxiga | $565 | $56,91070 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $36,21032 claims |
| PfizerEliquis, Premarin | $232 | $33,11155 claims |
| MerckJanumet, Januvia | $35 | $31,10230 claims |
| Johnson & JohnsonXarelto | $80 | $17,10514 claims |
| GSKTrelegy Ellipta | $75 | $7,64412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Columbia
- Conigliaro JonesColumbia$552K
- Damon DanielsColumbia$300K
- Andrew MartinColumbia$205K
- Ada StewartColumbia$186K
- Terry NagelColumbia$112K
- Steven BarnettColumbia$33K
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.